Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1172 ARTÍCULOS , VIENDO DEL 46 AL 60

APP processing in Alzheimer's disease

Zhang YW, Thompson R, Zhang H, Xu H.

Mol Brain. 2011 Jan 7;4:3. doi: 10.1186/1756-6606-4-3.

Post-translational modifications of tau protein: implications for Alzheimer's disease

Martin L, Latypova X, Terro F.

Neurochem Int. 2011 Mar;58(4):458-71. doi: 10.1016/j.neuint.2010.12.023. Epub 2011 Jan 6.

A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people

Kwok T, Lee J, Law CB, Pan PC, Yung CY, Choi KC, Lam LC.

Clin Nutr. 2011 Jun;30(3):297-302. doi: 10.1016/j.clnu.2010.12.004. Epub 2011 Jan 8.

Should we target insulin resistance to prevent dementia due to Alzheimer disease?

Luchsinger JA, Small S, Biessels GJ.

Arch Neurol. 2011 Jan;68(1):17-8. doi: 10.1001/archneurol.2010.339.

Current perspectives on pharmacotherapy of Alzheimer's disease

Chopra K, Misra S, Kuhad A.

Expert Opin Pharmacother. 2011 Feb;12(3):335-50. doi: 10.1517/14656566.2011.520702. Epub 2011 Jan 11.

Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'Onofrio G, Logroscino G, Seripa D, Pilotto A.

Expert Opin Investig Drugs. 2011 Mar;20(3):325-41. doi: 10.1517/13543784.2011.550572. Epub 2011 Jan 11.

Asymptomatic Alzheimer's disease: a prodrome or a state of resilience?

Driscoll I, Troncoso J.

Curr Alzheimer Res. 2011 Jun;8(4):330-5. doi: 10.2174/156720511795745348.

EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study

Vellas B, Sol O, Snyder PJ, Ousset PJ, Haddad R, Maurin M, Lemarié JC, Désiré L, Pando MP; EHT0202/002 study group.

Curr Alzheimer Res. 2011 Mar;8(2):203-12. doi: 10.2174/156720511795256053.

Neuronal membranes are key to the pathogenesis of Alzheimer's disease: the role of both raft and non-raft membrane domains

Williamson R, Sutherland C.

Curr Alzheimer Res. 2011 Mar;8(2):213-21. doi: 10.2174/156720511795256008.

Mitochondrion-specific antioxidants as drug treatments for Alzheimer disease

Palacios HH, Yendluri BB, Parvathaneni K, Shadlinski VB, Obrenovich ME, Leszek J, Gokhman D, Gąsiorowski K, Bragin V, Aliev G.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):149-62. doi: 10.2174/187152711794480474.

Alzheimer's disease: from pathogenesis to disease-modifying approaches

Galimberti D, Scarpini E.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):163-74. doi: 10.2174/187152711794480438.

Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: effects of the amyloid-β peptide of amyloid precursor protein

Robinson RA, Lange MB, Sultana R, Galvan V, Fombonne J, Gorostiza O, Zhang J, Warrier G, Cai J, Pierce WM, Bredesen DE, Butterfield DA.

Neuroscience. 2011 Mar 17;177:207-22. doi: 10.1016/j.neuroscience.2011.01.005. Epub 2011 Jan 9.

Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease

Blesa González R, Boada Rovira M, Martínez Parra C, Gil-Saladié D, Almagro CA, Gobartt Vázquez AL; en representación del grupo de investigadores del estudio kAPA.

Neurologia. 2011 Jun;26(5):262-71. doi: 10.1016/j.nrl.2010.10.007. Epub 2011 Jan 11.

Alzheimer's disease & metals: therapeutic opportunities

Kenche VB, Barnham KJ.

Br J Pharmacol. 2011 May;163(2):211-9. doi: 10.1111/j.1476-5381.2011.01221.x.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias